In a dramatic maneuver that blends corporate persistence with high-stakes biotech ambition, pharmaceutical contract manufacturer Future Pak LLC has publicly announced a sweeping proposal to acquire Theratechnologies Inc. for up to $255 million, despite what it calls “minimal engagement” from the Canadian biopharmaceutical company.

Unveiled Friday, this unsolicited offer represents Future Pak’s second attempt to initiate the deal, and comes with a bold appeal to shareholders—an effort to ignite movement where private talks fizzled.

A Game-Changing Premium Offer on the Table

According to the company’s statement, Future Pak is proposing to acquire all outstanding shares of Theratechnologies at a cash price between $3.51 and $4.50 per share, representing a 164% to 238% premium over Thursday’s closing price of $1.33.

The acquisition package includes:

• $205 million in cash at closing, and

• Up to $50 million in contingent value rights (CVRs), depending on future milestones.

"We’ve Been Patient — Now We're Public"

The move to go public follows months of what Future Pak calls a frustratingly one-sided courtship. Despite repeated outreach and what it describes as “compelling, premium-laden offers,” Theratechnologies has largely remained on the sidelines.

"We’ve submitted multiple proposals that offer flexibility and shareholder value," said Nirav Patel, Future Pak’s chief growth officer. "This is a genuine attempt to initiate meaningful, constructive dialogue toward a win-win transaction."

Theratechnologies’ Silence Sparks Shareholder Appeal

By lifting the veil of confidentiality, Future Pak hopes to rally Theratechnologies’ shareholders and increase pressure on the board to engage. The announcement, the company says, is designed to "ensure that the board fulfills its duty" in exploring paths to maximize shareholder value.

A Fully Backed, Fast-Moving Bid

The company emphasized that the offer carries no financing contingencies, thanks to backing from Colbeck Capital Management, Future Pak’s strategic financial partner.

If provided with sufficient due diligence access, Future Pak believes it could finalize a definitive agreement within four to six weeks.

Theratechnologies, which is headquartered in Montreal, did not respond to media requests for comment as of Friday.

A Clash of Pharma Visions

Founded in 1977, Future Pak operates as a privately held contract manufacturer and packager of pharmaceutical and nutraceutical products, headquartered in Wixom, Michigan. Meanwhile, Theratechnologies focuses on HIV treatments and is currently expanding into oncology research—two highly specialized therapeutic areas that would complement Future Pak’s manufacturing prowess.

Legal Advisors in the Shadows—for Now

Future Pak is being advised by Honigman LLP, although full legal counsel details were not disclosed. Theratechnologies’ legal representation also remains unnamed at this time, suggesting the chessboard is still in play and behind-the-scenes moves are underway.

As the clock ticks and shareholders weigh their options, one thing is clear: Future Pak isn’t backing down, and the biotech world is watching. This isn't just a takeover bid—it's a test of resolve, strategy, and the fine balance between boardroom diplomacy and shareholder advocacy.